Stockscreener 앱 받기
105.60
0.20%
0.15
전일 마감가:
$105.45
열려 있는:
$105.42
하루 거래량:
974.67K
Relative Volume:
0.30
시가총액:
$8.99B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
-52.80
EPS:
-2
순현금흐름:
$-103.81M
1주 성능:
+0.28%
1개월 성능:
+0.52%
6개월 성능:
+55.33%
1년 성능:
+290.24%
1일 변동 폭
$105.40
$105.67
1주일 범위
$105.23
$105.85
52주 변동 폭
$24.50
$105.85
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
105.56 | 9.12B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-01 | 개시 | Wolfe Research | Outperform |
| 2025-04-28 | 개시 | TD Cowen | Buy |
| 2025-04-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2024-10-03 | 개시 | Wells Fargo | Overweight |
| 2023-05-22 | 재개 | Jefferies | Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-26 | 개시 | Piper Sandler | Overweight |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Jefferies | Buy |
| 2020-08-10 | 개시 | Canaccord Genuity | Buy |
| 2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - MSN
Verona Pharma : Notice of Meetings and Proxy Statement in connection with proposed acquisition of Verona Pharma - MarketScreener
Verona Pharma stock reaches all-time high at 105.54 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 105.54 USD - Investing.com
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Verona Pharma ADR earnings beat by $0.11, revenue topped estimates - Investing.com Nigeria
Verona Pharma CFO Hahn sells $2.75 million in shares By Investing.com - Investing.com India
Verona Pharma (VRNA) director Ackermann sells $24k in shares - Investing.com
Verona Pharma CFO Hahn sells $2.75 million in shares - Investing.com
Verona Pharma director Cunningham sells shares for $142,057 By Investing.com - Investing.com South Africa
Verona Pharma (VRNA) director Deschamps sells $124,391 in shares - Investing.com India
Verona Pharma director Cunningham sells shares for $142,057 - Investing.com India
VERONA PHARMA PLCADR: Quantitative Momentum Investor Model Ratings - AInvest
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire Inc.
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com Australia
Verona Pharma stock reaches all-time high at 105.0 USD - Investing.com
Pharmaceutical Stocks To Research – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Wells Fargo Downgrades Verona Pharma plcDepositary Receipt () (VRNA) - MSN
Merck stock rises as UBS reiterates Buy rating after Verona Pharma acquisition By Investing.com - Investing.com South Africa
Merck to acquire Verona Pharma stock for $107 per ADS in $10 billion deal By Investing.com - Investing.com South Africa
Verona Pharma stock rating downgraded to Neutral by Roth/MKM after Merck offer - Investing.com South Africa
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact - Mitrade
Verona Pharma stock hits all-time high at 104.83 USD By Investing.com - Investing.com South Africa
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com Nigeria
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall By Investing.com - Investing.com South Africa
Merck compra por 10.000 millones de dólares Verona Pharma - Yahoo Finanzas
Best Momentum Stock To Buy For July 7th - Barchart.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - Yahoo Finance
Up 515%, Watch This Biopharma Breakout - inkl
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
Piper Sandler reiterates Verona Pharma stock rating and target By Investing.com - Investing.com UK
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Verona Pharma (VRNA) Shares Soar 5.47% to Record High - AInvest
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verona Pharma Plc Adr 주식 (VRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cunningham Kenneth | Director |
Aug 01 '25 |
Sale |
13.14 |
10,808 |
142,057 |
79,776 |
| Deschamps Lisa | Director |
Aug 01 '25 |
Option Exercise |
0.00 |
24,000 |
0 |
94,320 |
| Deschamps Lisa | Director |
Aug 01 '25 |
Sale |
13.14 |
9,464 |
124,392 |
84,856 |
| Fisher Andrew | General Counsel |
Aug 01 '25 |
Option Exercise |
0.00 |
20,888 |
0 |
427,487 |
| Fisher Andrew | General Counsel |
Aug 01 '25 |
Sale |
13.14 |
9,584 |
125,969 |
417,903 |
| Hahn Mark W | Chief Financial Officer |
Aug 01 '25 |
Option Exercise |
0.00 |
255,696 |
0 |
12,673,880 |
| Hahn Mark W | Chief Financial Officer |
Aug 01 '25 |
Sale |
13.14 |
208,912 |
2,745,877 |
12,464,968 |
| Rickard Kathleen A. | Chief Medical Officer |
Aug 01 '25 |
Option Exercise |
0.00 |
70,888 |
0 |
2,665,808 |
| Rickard Kathleen A. | Chief Medical Officer |
Aug 01 '25 |
Sale |
13.14 |
58,336 |
766,751 |
2,607,472 |
| ACKERMANN CHRISTINA | Director |
Aug 01 '25 |
Option Exercise |
0.00 |
24,000 |
0 |
65,880 |
0.94%
1.72%
자본화:
|
볼륨(24시간):